IGFBP-2: The dark horse in metabolism and cancer
- 1 June 2015
- journal article
- review article
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 26 (3) , 329-346
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council (NHMRC) of Australia (#1008062)
- National Health and Medical Research Council Professional Training Fellowship (APP1012201)
This publication has 189 references indexed in Scilit:
- The central role of calcium in the effects of cytokines on beta-cell function: Implications for type 1 and type 2 diabetesCell Calcium, 2011
- High IGFBP2 Expression Correlates with Tumor Severity in Pediatric RhabdomyosarcomaThe American Journal of Pathology, 2011
- Insulin-like growth factor-binding protein-2 is required for osteoclast differentiationJournal of Bone and Mineral Research, 2011
- Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxelBritish Journal of Cancer, 2011
- Crosstalk between insulin receptor and G protein-coupled receptor signaling systems leads to Ca2+ oscillations in pancreatic cancer PANC-1 cellsBiochemical and Biophysical Research Communications, 2010
- Extracellular calcium sensing receptor stimulation in human colonic epithelial cells induces intracellular calcium oscillations and proliferation inhibitionJournal of Cellular Physiology, 2010
- IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomasProceedings of the National Academy of Sciences, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancerProceedings of the National Academy of Sciences, 2007
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002